Qualitek Labs share price today

Qualitek Labs Ltd's share price was ₹500.00 at the close on 4 November 2026. It has been rising for 23 weeks. That is 12.5% above its average price over the last 200 trading days. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 16 weeks in a row.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Qualitek Labs Ltd is in stage 2. The phase helps read everything below.

Since its first close in our records, on 8 May 2026, it has traded between ₹340 and ₹621, and at that close it sat 57% of the way up from that low.

Over the last 6 months the share price moved +47% while the NIFTY 500 moved −3%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Two changes stood out: revenue up on a year earlier for 5 quarters in a row (every quarter we can compare) and operating margin down 3 points on a year earlier.

1. Revenue up on a year earlier for 5 quarters in a row (every quarter we can compare)

   In the March 2026 quarter revenue was ₹39 crore, +54.9% on a year earlier.

2. Operating margin down 3 points on a year earlier

   26% in the March 2026 quarter, from 29%.

For January to March 2026 (the quarter ended 31 March 2026), Qualitek Labs reported revenue of ₹38.6 crore, up 54.9% from ₹24.9 crore a year earlier, and a profit of ₹5.17 crore, up 44.8% from ₹3.57 crore.

Qualitek Labs results: January to March 2026 against a year earlier

The next results, for April to June 2026, were due by 14 August 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). This page shows them once our weekly data update has read them.

From the company's reported quarterly results (quarter ended 31 March 2026). Revenue and profit in ₹ crore.

Qualitek Labs closed at ₹500.00 on 4 November 2026. Its highest weekly close since May 2026 was ₹621.00 on 25 September 2026.

Qualitek Labs share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

29 weekly closes from 8 May 2026 to 4 November 2026.

4 Nov 2026: Qualitek Labs closed at ₹500.00, up 1.0% on the week and down 13.6% on the month. Our read, 10 Oct 2026: Reported expansion is visible, but acquisition effects, funding needs and limited reporting history prevent a confirmed self-funded growth thesis.

Earlier

• Results for January to March 2026: Revenue up 54.9% and profit up 44.8% on a year earlier.

Our read of the business

January to March 2026: Reported second-half profitability improved; this is a half-year observation.

Our read after the January to March 2026 results, written 10 October 2026.

No. Qualitek Labs Ltd paid out 0% of its profit as dividends in each of its last 6 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate (as of 4 November 2026).

Qualitek Labs' management made 0 promises we could check against what it later reported.

Our read after the January to March 2026 results, written 10 October 2026.

What is changing at Qualitek Labs, from the latest results and calls: reported platform expansion, potential improvement in service economics and cash conversion of existing earnings.

• Reported platform expansion. Revenue and operating profit increased together. ⚠ estimate
• Cash conversion of existing earnings. Operating cash broadly tracks profit before expansion spending. ⚠ estimate
• Forward execution goal. A numerical growth and profit-margin goal makes the next annual result testable. ⚠ estimate

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown.

Our read after the January to March 2026 results, written 10 October 2026.

A comparable reporting period showing lower operating profit while borrowings and overdue receivables increase would break the case that expansion is creating sustainable shareholder value.

Each change stops working if

• Reported platform expansion: Comparable revenue stalls while depreciation, interest and operating costs continue rising.
• Cash conversion of existing earnings: Operating cash falls behind profit while receivable ageing deteriorates.
• Forward execution goal: Management reduces its goal or the comparable result fails to show the required operating contribution.

The main risks

• : The thin-history lead remains unresolved. ⚠ estimate
• : Cash conversion does not establish self-funded expansion. ⚠ estimate
• : Collections remain a material use of capital. ⚠ estimate
• : Reported scale can outrun per-share value creation. ⚠ estimate

Our read after the January to March 2026 results, written 10 October 2026.

When Qualitek Labs reports April to June 2026, these are the 5 checks that show whether the story is still on course. First: The next filing still lacks an acquisition-adjusted comparison and a usable prior-period bridge.

Qualitek Labs is on one of our India lists: Multibagger study list.

Qualitek Labs Ltd earned ₹5.2 Cr of net profit in the Mar 2026 quarter, +44.8% on the same quarter a year earlier. That is the 3rd quarter in a row of profit growth. Full-year FY26 profit was ₹8.0 Cr. Over 5 years profit has grown 76.9% a year on average. That is 13.4% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹2.3 Cr.

For the full year, FY26 profit was ₹8.0 Cr (+50.8% on the year before).

Why profit moved: revenue changed +54.9% on a year earlier and the margin moved −3.0 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed +37.2% and revenue +52.6%. Profit is growing slower than sales: rising costs are taking part of the growth.

FY26-Q2. revenue ₹29 Cr and profit ₹3 Cr as reported.

FY26-Q4. revenue ₹39 Cr and profit ₹5 Cr as reported.

Why-sources: our stock research file (10 October 2026) and the company’s own results for those quarters.

Qualitek Labs Ltd reported ₹38.6 Cr of revenue in the Mar 2026 quarter, +54.9% on the same quarter a year earlier. That is the 5th quarter in a row with growth on the year before. Over 5 years it has grown 60.5% a year on average. The last full year, FY26, came in at ₹67.6 Cr.

Revenue is everything the company billed its customers in the period.

Why this happened. Management proposed an inspection business with a dated start. The potential benefit depends on customer wins, staff costs and collections; competitors' pricing response and retained profit are unknown. The promise is an opportunity to verify rather than delivered incremental cash.

FY26 revenue was ₹67.6 Cr, +47.4% on the year before.

Recent pace: the last four quarters grew +52.6% on average, against 60.5% a year over the longer run, so this year is growing slower than its own long-run rate.

FY26-Q2. revenue ₹29 Cr and profit ₹3 Cr as reported.

FY26-Q4. revenue ₹39 Cr and profit ₹5 Cr as reported.

Why-sources: our stock research file (10 October 2026) and the company’s own results for those quarters.

Qualitek Labs Ltd's operating margin was 25.9% in the Mar 2026 quarter, 3.0 percentage points lower than the same quarter a year ago. Over the last four quarters it has moved +0.1 percentage points. Across 6 years it has been between 16.2% and 27.7%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why this happened. The goal provides a measurable hurdle. Its first contribution must appear in comparable operating results and attributable earnings. No separate valuation benefit is assumed merely because management published guidance.

Why the margin moved: operating margin changed +0.1 percentage points on the year while gross margin changed −16.6 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

FY26-Q2. revenue ₹29 Cr and profit ₹3 Cr as reported.

FY26-Q4. revenue ₹39 Cr and profit ₹5 Cr as reported.

Why-sources: our stock research file (10 October 2026) and the company’s own results for those quarters.

Over the last 3 years, 118% of Qualitek Labs Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹7.2 Cr of operating cash against ₹8.0 Cr of profit.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Why this happened. Cash conversion supports the existing earnings base. Collection improvement would preserve more of the operating benefit.

After ₹45.0 Cr of spending on assets, free cash was −₹38.0 Cr: it spent more than its operations brought in.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 118% of profit came in as cash: the cash cycle got 37 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: the bigger use of cash is spending on new assets, at 8.3× depreciation over three years. The next section checks what that spending is building.

Qualitek Labs Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 106 days in FY26, up from 69 days in FY21. It spent ₹75.0 Cr on assets over the last 3 years. Customers take 106 days to pay, and stock sits for 70 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Why this happened. Operating profit growth accompanies revenue growth, which supports a business contribution to earnings. Full-period subsidiary consolidation prevents treating the entire increase as organic demand. Acquisition scale and utilization are dependent mechanisms and are counted together.

At FY26 sales of ₹67.6 Cr, each day of that cycle ties up about ₹0.2 Cr, so roughly ₹20.0 Cr is tied up in the business at any time.

FY26: customers took 106 days to pay and stock sat for 70 days, about 2.3 months of sales sitting as stock, for a full cycle of 106 days, longer than FY21's 69.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 70 days. Customers pay about 106 days after that. Suppliers are paid at 206 days. Together that makes the 106-day cycle.

Spending on assets: ₹75.0 Cr over the last 3 years, against ₹9.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹41.9 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Qualitek Labs Ltd's P/E is 72.2×, in the middle of its own history: higher than 52% of past readings. Its usual P/E (the middle reading) is 71.3×, over 2.7 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple.

Qualitek Labs Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 5 quarters of 1 measure, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Qualitek Labs Ltd's story is not scored yet against the checks our research set on 10 October 2026. Where it sits in its own cycle: MID EXPANSION. Still open: A comparable reporting period showing lower operating profit while borrowings and overdue receivables increase would break the case that expansion is creating sustainable shareholder value.

NOT YET CHECKED

Our read, 10 October 2026. Reported expansion is visible, but acquisition effects, funding needs and limited reporting history prevent a confirmed self-funded growth thesis.

From the numbers. The operating-stage estimate indicates expansion, but comparable earnings history remains…

From the price. Price stage 2, week 23, above its 200-day line, relative strength rising.

From the research. Reported expansion is visible, but acquisition effects, funding needs and limited reporting history prevent a confirmed self-funded growth thesis.

Where they disagree. The operating-stage estimate indicates expansion, but comparable earnings history remains insufficient.

What is proven. Reported expansion is visible, but acquisition effects, funding needs and limited reporting history prevent a confirmed self-funded growth thesis.

What is not proven yet. A comparable reporting period showing lower operating profit while borrowings and overdue receivables increase would break the case that expansion is creating sustainable shareholder value.

What would change our mind. A comparable reporting period showing lower operating profit while borrowings and overdue receivables increase would break the case that expansion is creating sustainable shareholder value.

The test written in advance. A comparable reporting period showing lower operating profit while borrowings and overdue receivables increase would break the case that expansion is creating sustainable shareholder value. Measured by: the thesis as written as stated by the next result.

What the company does. The testing platform has increased reported revenue and operating profit. The deeper question is how much growth remains after consolidation effects, additional shares and funding costs.

The key numbers to watch, and the level that would change the picture

Everything further down this page is evidence for or against these.

What the surface reading misses. The surface reading is: Reported annual growth suggests expansion. The research reads it further: Revenue and operating profit moved together, but the consolidation perimeter changed. Reported growth therefore mixes operating delivery with acquired scale.

What the surface reading misses. The surface reading is: Profit growth exceeds the acceleration threshold. The research reads it further: Operating-profit growth tracks profit growth, but acquired revenue and additional ownership can explain part of the increase.

Sources: our stock research file (10 October 2026) · quarterly results through Mar 2026. The story check is re-scored every results season; the record below never changes.

The whole page in one table. Each row links to its section.

Qualitek Labs Ltd earned a ROCE of 8% in FY26. Its return on capital used (ROIC) is 2.4 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 11.8% net margin and 0.30× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 11.8% net margin × 0.30× asset turnover × 1.54× leverage (assets divided by equity) ≈ 5.5% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 9.6% − 12.0% = −2.4 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve.

Qualitek Labs Ltd had ₹65.6 Cr of borrowings against ₹146 Cr of equity in FY26, so its debt is 0.45× its equity. Its operating profit is 7 times its interest bill. Over 5 years borrowings went from ₹11.2 Cr to ₹65.6 Cr. Over the last 3 of those years it spent ₹75.0 Cr on assets.

Debt-to-equity shows how much of the business is paid for with borrowed money. Interest cover shows how many times operating profit pays the interest bill. Low debt and high cover are the safe combination.

Part of the spending on assets is being paid for with borrowed money.

Promoters cut their stake in Qualitek Labs Ltd by 16.9 percentage points over 5 quarters, the biggest change among its owners. Promoters now own 56.5% of the company. Foreign institutions moved +1.5 points over the same period, to 1.5%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Promoters: −16.9 points over 5 quarters, to 56.5%; Foreign institutions: +1.5 points over 5 quarters, to 1.5%; Domestic institutions: +0.1 points over 5 quarters, to 0.1%.

Why the owners changed: promoters drove it (−16.9 points), with the other side taken by foreign institutions (+1.5 points). They reduced their stake.

For Qualitek Labs Ltd, the Z-score is 2.64. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the grey area between the two. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of 2.64 is in the grey area, neither clearly safe nor clearly in trouble.

There is no score against its industry: Qualitek Labs Ltd is not present in the sector comparison for Miscellaneous.

The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown.

No sector comparison is shown here, not present in the sector comparison.

Qualitek Labs is the 32nd largest of 42 Miscellaneous companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Stanley Lifestyles, Global Education and IIRM Holdings India. Just below it: Maagh Advertising & Marketing Services, Blue Water Logistics and Fabtech Cleanrooms.

Miscellaneous companies close in size

29. Stanley Lifestyles Ltd ₹739 crore
30. Global Education Ltd ₹732 crore
31. IIRM Holdings India Ltd ₹728 crore
32. Qualitek Labs Ltd ₹577 crore
33. Maagh Advertising & Marketing Services Ltd ₹572 crore
34. Blue Water Logistics Ltd ₹550 crore
35. Fabtech Cleanrooms Ltd ₹548 crore

All 42 Miscellaneous companies, largest first

Companies close in size in other industries

1936. Goel Construction Company Ltd ₹578 crore · Engineering - Turnkey Services
1937. JTL Defence Ltd ₹578 crore · Metal - Copper/Copper Alloy Products
1938. Qualitek Labs Ltd ₹577 crore
1939. Voith Paper Fabrics India Ltd ₹577 crore · Textiles - General
1940. Artson Ltd ₹576 crore · Infra - Engineering - General

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.